Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters.Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ: SYRE),…
Spyre Therapeutics’ $200 Million Common Stock Offering
Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters.Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ: SYRE),…